Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation

Chemoimmunotherapy is the first-line standard treatment for patients with non-small cell lung cancer (NSCLC). However, there are few reports on the efficacy of chemoimmunotherapy in patients with NSCLC who harbor the MET exon 14 skipping mutation. We report the case of an 81-year-old male patient wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nitta, Naohiro, Morimoto, Yoshie, Tani, Nozomi, Shimamoto, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058577/
https://www.ncbi.nlm.nih.gov/pubmed/37007311
http://dx.doi.org/10.7759/cureus.35545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058577/
https://www.ncbi.nlm.nih.gov/pubmed/37007311
http://dx.doi.org/10.7759/cureus.35545

Ejemplares similares